Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
By Christoph Sarrazin, Tara L. Kieffer, D. Bartels, B. Hanzelka, U. Müh, M. Welker, D. Wincheringer, Yi Zhou, H. Chu, Chao Lin and 4 more. Gastroenterology, 2007
661 citations recorded by the source corpus.
Subfields: Hepatology, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/8f24cb567fdc562bd802e231649293253446b23f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
Citations in the corpus
- An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011, background): “In phase 3 studies, the emergence of resistant variants and virological breakthrough was more common in patients infected with HCV subtype 1a than 1b, a result of a higher genetic barrier required for selection of resistant variants in HCV subtype 1b compared to 1a.(28) Thus, HCV subtyping may play ”